Researchers have developed a Cx43-M2 activating antibody, which significantly increased the number and function of tumor-infiltrating effector T cells while reducing immunosuppressive regulatory T cells, resulting in a substantial enhancement of the anti-tumor immune response (91–93). Here, GJA1 is linked to neoplasm.